Open AccessEfficacy and safety of oral gemifloxacin for the empirical treatment of pneumonia
Author(s) -
Vindu Amitabh,
Anish Singhal,
Shivam Kumar,
Narmada Prasad Patel,
Yasir Rizvi,
Pankaj Mishra
Publication year - 2012
Publication title -
lung india
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 25
eISSN - 0974-598X
pISSN - 0970-2113
DOI - 10.4103/0970-2113.99109
Subject(s) - gemifloxacin , medicine , pneumonia , community acquired pneumonia , respiratory tract infections , antibiotics , intensive care medicine , antibacterial agent , respiratory system , microbiology and biotechnology , biology
Respiratory tract infections (RTI) are common causes of morbidity and mortality worldwide. Initial antibiotic therapy in upper and lower respiratory tract infections is usually empirical. The increasing evidence of antibacterial resistance in the pathogens commonly associated with pneumonia has raised concerns about the efficacy of currently available therapies and poses a challenge to clinicians. Gemifloxacin is a synthetic fluoroquinolone antimicrobial agent exhibiting potent activity against most Gram negative and Gram positive organisms. Hence, this study was planned to evaluate the efficacy of gemifloxacin as an empirical therapy in pneumonia.